Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-5960
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease ; volume:10 ; number:1 ; day:22 ; month:6 ; year:2022 ; pages:1-13 ; date:12.2022
Acta Neuropathologica Communications ; 10, Heft 1 (22.6.2022), 1-13, 12.2022
- Urheber
-
Hall, Sara
Orrù, Christina D.
Serrano, Geidy E.
Galasko, Douglas
Hughson, Andrew G.
Groveman, Bradley R.
Adler, Charles H.
Beach, Thomas G.
Caughey, Byron
Hansson, Oskar
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40478-022-01388-7
- URN
-
urn:nbn:de:101:1-2022081422360192495347
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hall, Sara
- Orrù, Christina D.
- Serrano, Geidy E.
- Galasko, Douglas
- Hughson, Andrew G.
- Groveman, Bradley R.
- Adler, Charles H.
- Beach, Thomas G.
- Caughey, Byron
- Hansson, Oskar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)
Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology
External validation of a 3-step falls prediction model in mild Parkinson’s disease
Towards a unified protocol for handling of CSF before β-amyloid measurements
Fluid biomarkers in Alzheimer’s disease – current concepts
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Novel insights regarding the measurement properties of the SCOPA-AUT
The clinical significance of 10-m walk test standardizations in Parkinson’s disease
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)
Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology
External validation of a 3-step falls prediction model in mild Parkinson’s disease
Towards a unified protocol for handling of CSF before β-amyloid measurements
Fluid biomarkers in Alzheimer’s disease – current concepts
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Novel insights regarding the measurement properties of the SCOPA-AUT
The clinical significance of 10-m walk test standardizations in Parkinson’s disease
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)
Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology
External validation of a 3-step falls prediction model in mild Parkinson’s disease
Towards a unified protocol for handling of CSF before β-amyloid measurements
Fluid biomarkers in Alzheimer’s disease – current concepts
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Novel insights regarding the measurement properties of the SCOPA-AUT